CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 76 filers reported holding CUE BIOPHARMA INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $163,000 | -56.9% | 33,500 | +0.3% | 0.00% | – |
| Q4 2021 | $378,000 | -22.4% | 33,400 | 0.0% | 0.00% | – |
| Q3 2021 | $487,000 | +25.2% | 33,400 | 0.0% | 0.00% | – |
| Q2 2021 | $389,000 | +11.5% | 33,400 | +16.8% | 0.00% | – |
| Q1 2021 | $349,000 | -12.5% | 28,600 | -10.3% | 0.00% | – |
| Q4 2020 | $399,000 | -16.9% | 31,900 | 0.0% | 0.00% | – |
| Q3 2020 | $480,000 | -45.0% | 31,900 | -10.4% | 0.00% | -100.0% |
| Q2 2020 | $873,000 | +366.8% | 35,600 | +169.7% | 0.00% | – |
| Q1 2020 | $187,000 | – | 13,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 820,000 | $11,636,000 | 12.56% |
| Prosight Management, LP | 552,060 | $7,834,000 | 3.66% |
| Nantahala Capital Management | 2,503,840 | $35,529,000 | 1.33% |
| MANGROVE PARTNERS IM, LLC | 601,398 | $8,534,000 | 1.18% |
| Voss Capital, LLC | 88,670 | $749,000 | 1.00% |
| Slate Path Capital LP | 870,694 | $12,355,000 | 0.95% |
| Avoro Capital Advisors LLC | 1,870,000 | $26,535,000 | 0.90% |
| Bleichroeder LP | 165,000 | $2,341,000 | 0.61% |
| 683 Capital Management, LLC | 640,000 | $9,082,000 | 0.54% |
| PA Capital LLC | 40,706 | $578,000 | 0.51% |